Guselkumab and Golimumab: Better Together for Ulcerative Colitis

People with moderate-to-severe ulcerative colitis benefit from a combination of these monoclonal antibodies, compared with induction with either agent alone, according to a new phase 2a study.

Related Keywords

Ohio ,United States ,Charlotte ,North Carolina ,Canada ,London ,City Of ,United Kingdom ,Briang Feagan ,Jean Paul Achkar ,American College Of Gastroenterology ,Alimentiv Inc ,Western University ,American College ,Scientific Meeting ,Findings Through Week ,Mayo Score ,Paul Achkar ,Inflammatory Bowel Disease ,Cleveland Clinic ,Kenneth Rainin Endowed Chair ,Medscape Medical News ,Ulcerative Colitis ,Nflammatory Bowel Disease Ibd ,Bd ,Biologic Therapy ,Monoclonal Antibody ,Etuximab ,Ituximab ,Interleukin Antagonist ,L Antagonist ,Anti Tnf ,Anti Tumor Necrosis Factor ,Crohns Disease ,Gastrointestinal Disease ,Di Disease ,Clinical Research ,Clinical Trials ,Linical Studies ,Medical Literature ,Books ,Textbooks ,Ournals ,